This single-institute retrospective study of 89 patients who received reduced-intensity conditioning with the fludarabine/melphalan/total body irradiation regimen, shows favorable transplant outcomes with a relatively low risk of transplant-related toxicities. This combination may be a promising strategy for patients with relapsed or refractory aggressive non-Hodgkin lymphoma. Introduction: Allogeneic hematopoietic stem cell transplant with reduced-intensity conditioning is an effective therapeutic option for patients with refractory or relapsed aggressive non-Hodgkin lymphoma (NHL). Patients and Methods: We retrospectively evaluated survival outcomes and the efficacy of our fludarabine/melphalan/total body irradiation (TBI) (FMT) regimen. A total of 89 patients had received the FMT regimen from 2007 to 2017. Results: The majority of patients (n ¼ 81; 91%) belonged to the histologic subtype of aggressive NHL. The estimated 3-year overall survival and disease-free survival for the entire cohort during a median follow-up of 31 months were 47.1% (95% confidence interval, 36%-57%) and 45.4% (95% confidence interval, 35%-56%), respectively. The cumulative incidence rates of relapse and non-relapse mortality at 3 years were 33.1% and 13.8%, respectively. In analyses of risk factors affecting survival outcomes, chemosensitive disease status at transplant (hazard ratio [HR], 2.45; P ¼ .010), delayed relapse after first-line chemotherapy (HR, 2.101; P ¼ .009), no grade III to IV acute graft-versus-host disease (HR, 11.212; P < .001), and mild chronic graft-versus-host disease (HR, 0.448; P ¼ .016) were independent significant predictors of favorable overall survival. Also, similar parameters were related to favorable disease-free survival. All non-hematologic toxicities occurred within 50 days after allogeneic hematopoietic stem cell transplant, and most of the adverse events were tolerable and manageable with a < 30% incidence. Conclusion: Our FMT regimen shows favorable transplant outcomes with relatively low-risk toxicities, so it may be a promising strategy for patients with relapsed or refractory aggressive NHL.
Introduction
Hematopoietic stem cell transplantation (HSCT) for patients with non-Hodgkin lymphoma (NHL) has been largely dominated by autologous HSCT therapeutic strategy. Patients who receive high-dose chemotherapy and autologous HSCT (auto-HSCT) have 1.1-to 1.5-fold improved survival outcomes compared with those who undergo conventional chemotherapy, with acceptable toxicities for aggressive and advanced NHL. 1 However, therapeutic options for patients with primary refractory or relapsed NHL compared with traditional chemotherapy are limited, and long-term follow-up studies after auto-HSCT suggest that progression-free survival (PFS) is controversial in some cases. 2 In comparison with auto-HSCT, allogeneic HSCT (allo-HSCT) has favorable advantages; it reduces the chance of relapse by avoiding tumor contamination by autograft, and it is believed that the immune-mediated graft-versus-lymphoma (GVL) effects of allo-HSCT help reduce the risk of relapse. 3, 4 Still, allo-HSCT is considered the most effective therapeutic option for patients with refractory or relapsed NHL after chemotherapy or auto-HSCT because long-term survival rates are 40% to 50% in this group of patients. 5, 6 On the other hand, minimizing treatment-related mortality or morbidity by allo-HSCT is considered to be an important factor in increasing the response rate of treatment. However, the majority of studies were small cohorts and incorporated patients with heterogeneous natures. Generally, the use of allo-HSCT in patients with NHL depends on several factors, including age, disease status, comorbidities, and performance status. Moreover, because NHL is a heterogeneous group of tumors with various physiologic features, the histologic types of NHL are an important factor. Numerous previous studies had suggested that allo-HSCT improves the prognosis mainly focused on indolent histologic subtypes such as follicular lymphoma or mantle cell lymphoma. [7] [8] [9] These studies have reported that reduced-intensity conditioning (RIC) regimens result in favorable therapeutic outcomes with acceptable treatment-related mortality and lower relapse incidences, and that these results are partially caused by the GVL effect during the RIC regimen in patients with mainly indolent subtypes. 10 The range in intensity and myelosuppression of RIC regimens for NHL varies [11] [12] [13] from a mild suppressive degree using fludarabine plus busulfan, to a more intensified sequential regimen using busulfan plus intermediate-dose total body irradiation (TBI). Based on these results, various RIC regimens are often used in patients undergoing allo-HSCT for indolent NHL.
However, few reports have been reported on the benefit of allo-HSCT in an aggressive subtype of NHL. 4, 14 In particular, there is little information available about allo-HSCT on histologically aggressive subtypes such as peripheral T cell lymphoma, natural killer cell lymphoma, and anaplastic large cell lymphoma, which occurs relatively frequently in Asian regions. Thus, we have used a homogeneous RIC regimen over the years, and recently reported acceptable survival outcomes for allo-HSCT in patients with relapsed or refractory aggressive subtypes of NHL who underwent a uniform regimen with a fludarabine/melphalan/ TBI (FMT) regimen. 15 In the present study, we conducted retrospective analyses of survival outcomes from a single institute-based standard RIC (FMT regimen) for relapsed or refractory aggressive NHL, with a relatively large number of patients and an extended follow-up duration compared with previous studies. We also identified predictors of transplant outcome in patients undergoing RIC with the FMT regimen.
Patients and Methods

Patient Selection
We searched for patients > 18 years who had undergone allo-HSCT for refractory or relapsed NHL from January 2007 to November 2017 at our institute. Patients who were diagnosed with pathologic NHL and received the RIC regimen during allo-HSCT were included in this analysis. Extended observations were performed until May 2018 to ensure a subsequent minimum follow-up duration of at least 6 months. Clinical information was obtained from electronic medical records, including age at diagnosis, histopathologic diagnosis, details of prior chemotherapy regimens, response to chemotherapy, the status of auto-HSCT, disease status at transplantation, the source of hematopoietic stem cells, and survival outcome details. This study was approved by the Institutional Review Board of Seoul St. Mary's Hospital of The Catholic University of Korea in accordance with the Declaration of Helsinki. Eighty-nine refractory or relapsed patients who had undergone allo-HSCT with the FMT regimen after various salvage chemotherapies were included. The pathology was confirmed by experienced lymphoma pathologists according to the 2008 World Health Organization classification.
Conditioning Regimens and Graft-Versus-Host Disease (GVHD) Prophylaxis
Human leukocyte antigen (HLA) matching was performed using a well-known method; "well-matched" was defined by non-disparity between the donor and recipient at HLA-A, B, C, and DR1 (8/8); "partially matched" was 1 known or 1 likely disparity; and "mismatched" included 2 or more disparities. Haploidentical donors were associated with donors with a 6e4/8 HLA matching degree. 16 The standard RIC FMT regimen used at our institution consisted of 30 Survival Outcomes of Allo-HSCT With FMT Regimen for Aggressive NHL case, they also underwent the same FMT conditioning regimen. GVHD prophylaxis was entirely the same as the prophylaxis for HLA-matched donors. All patients were managed in a specific sterilized room with laminar air-flow and high-efficacy air purification filters. Acyclovir and itraconazole were prescribed to all patients for viral and fungal prophylaxis. All patients received filgrastim as granulocyte-colony stimulating factor beginning on the day when the absolute neutrophil count (ANC) was < 500/mL at a dose of 5 mg/kg/day subcutaneously until the ANC was > 1000/mL.
Moreover, other conservative management was performed for each event.
Chemotherapy Strategy and Response Assessment
The following therapeutic approach was used for patients with NHL. After frontline chemotherapy failure, ifosfamide/carboplatin/ etoposide and dexamethasone/high-dose cytarabine/cisplatin basedregimens were alternatively used for salvage chemotherapy. Therapeutic response and disease progression were assessed according to the revised version of the International Working Group response criteria for malignant lymphoma, 17 based on a computed tomography scan, positron emission tomography scan, and clinical examinations. No routine molecular biology examination tools were used. Disease status was evaluated at the time of allo-HSCT according to chemosensitivity; chemosensitive disease was defined as achieving complete remission (CR) or partial remission (PR), and chemorefractory disease included primary refractory disease or refractory relapse before transplant.
Evaluation of Survival Outcomes and Transplant-related Risks
Survival outcomes were evaluated according to overall survival (OS), progression-free survival (PFS), cumulative incidence of acute or chronic GVHD, relapse, and non-relapse mortality (NRM). Also, transplant-related risk factors were calculated using the European Society for Blood and Marrow Transplantation scoring system, including the factors of age at diagnosis and HSCT, pre-HSCT status, and donor-recipient combinations. 18 Chemotherapy-related toxicities were determined based on the National Cancer Institute Common Toxicity Criteria for Adverse Events (version 4.0). Acute GVHD and chronic GVHD after transplantation were graded according to the system of Glucksberg/ Thomas and the National Institutes of Health Consensus.
19,20
Statistical Analyses
Surviving patients were censored on the last day of follow-up. All categorical variables were compared using the c 2 or Fisher exact test, which are expressed as proportions. The continuous variables were analyzed using the Mann-Whitney U test between the 2 groups, and are expressed as medians with ranges. OS and DFS were calculated using the Kaplan-Meier survival method with log-rank analyses. The Cox regression model was used for univariate and multivariate analyses to determine the independent effects on OS and DFS. Cumulative incidence estimates of acute GVHD, chronic GVHD, relapse, and NRM were calculated with relapse or death from other causes defined as competitive events using the Gray test for univariate analyses and the Fine-Gray method for proportional hazard regression analyses. The impact of acute and chronic GVHD on relapse and NRM was calculated using the Cox proportion hazard method with time-dependent covariate to avoid several biases. Differences were considered significant at a 2-sided P < .05. 
Results
Patient and Transplant Characteristics
Overall, 89 patients with aggressive NHL who underwent allo-HSCT and received the FMT regimen as RIC were included. In terms of baseline characteristics, the median age at initial diagnosis was 45 years (range, 18-64 years), and there was a predominance of males (59 males and 30 females). Disease-related characteristics are detailed in Table 1 . In all, B cell type NHL and T cell lineage NHL were analyzed in 42 patients, respectively, in the same number of patients, and each histologic subtype was also described in Table 1 . Of these, 81 (91%) patients were aggressive histologic subtypes. Table 2 . In terms of stem cell sources, only 5 (5.6%) patients of the HLA-identical sibling transplants were transplanted with BM stem cells. The remaining 84 (94.4%) patients, including all haploidentical transplants, received transplantation using peripheral blood stem cell source. Also, all of the stem cells were infused without additional CD34 selection.
Hematologic Recovery and Engraftment
All patients were evaluable for hematopoietic recovery and chimerism status. Patients received a median of 7.58 Â 10 6 CD34þ cells/kg (range, 2.91 Â 10 6 to 16.98 Â 10 6 CD34þ cell/kg). The median time to both absolute neutrophil count recovery (ANC > 500/mL) and platelet recovery (> 50,000/mL for 3 consecutive days without a blood transfusion) was 13 days (range, 7-69 days after receiving the FMT regimen). No engraftment failures were observed after allo-HSCT with the FMT regimen: chimerism results were available for all 89 patients from the patient's peripheral blood sample at the first testing (range, 28-80 days after allo-HSCT), and full donor chimerism (! 97% donor cells) was completed successfully in all patients.
Survival Outcomes After Allo-HSCT in All Cohorts
In all, 43 (48.3%) of 89 patients had survived over a median follow-up of 41 months (range, 7-135 months); 41 (46.1%) patients had no evidence of lymphoma at the last follow-up. The estimated 3-year OS and DFS rates of the entire cohort were 47.1% (95% confidence interval [CI], 36%-57%) and 45.4% (95% CI, 35%-56%), respectively ( Figure 1 ). Survival analyses were conducted for each NHL-related factor to identify differences in transplant
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Clinical Lymphoma, Myeloma & Leukemia Month 2019 -3 outcomes based on the clinical characteristics of NHL. There were no differences among the pathologic subtypes of T-cell and B-cell type NHL (P ¼ .233 for OS; P ¼ .132 for DFS) (see Supplemental Figure 1 in the online version), and no differences in survival outcome were observed between the indolent and aggressive subtypes Figure 1 in the online version). Moreover, a short relapse interval (< 12 months) after first-line chemotherapy was associated with inferior OS and DFS (P ¼ .027 for OS; P ¼ .021 for DFS) (see Supplemental Figure 2 in the online version). However, BM involvement at initial diagnosis did not affect OS or DFS (P ¼ .213 for OS; P ¼ .123 for DFS) (see Supplemental Figure 1 in the online version), and no differences in survival outcomes were observed between patients who underwent allo-HSCT after auto-HSCT failure and auto-HSCT-naive patients (P ¼ .954 for OS; P ¼ .631 for DFS) (see Supplemental Figure 2 in the online version). No significant differences in OS or PFS were observed at 3 years for patients who had received transplants from well-matched or haploidentical donors (OS, P ¼ .067; DFS, P ¼ .162) (see Supplemental Figure 3 in the online version). The causes of death were lymphoma relapse or lymphoma progression (n ¼ 27; 58.7%), severe infection (n ¼ 9; 19.6%), grade III to IV acute GVHD (n ¼ 5; 10.9%), veno-occlusive disease (n ¼ 2; 4.3%), lung GVHD (n ¼ 1; 2.2%), and others (hypertensive brain hemorrhage and acute myocardial infarction). Nineteen patients died of non-relapse causes; the most common causes of NRM were infection (n ¼ 9) and acute GVHD (n ¼ 5). When defining an early NRM as events occurring within 100 days after allo-HSCT, the early NRM was 2.8%; moreover, the cumulative incidence rates of NRM at 1 and 3 years as mid-to long-term were 10.0% (95% CI, 4.4%-18.4%) and 13.8% (95% CI, 6.6%-23.5%), respectively ( Figure 1 ).
GVHD Incidence and FMT Regimen-related Toxicities
Thirty (33.7%) patients developed any grade of acute GVHD (19 patients, grade I; 11 patients, grades II-IV) with a cumulative incidence of 34.2% at 1 year after allo-HSCT (Table 3, Figure 2 ). Of the 89 patients at risk for chronic GVHD, 47 (52.8%) developed some stage of chronic GVHD, with a cumulative incidence of 27.0% at 3 years after allo-HSCT; 31 developed limited chronic GVHD, and 16 developed extensive chronic GVHD, including 1 patient with lung GVHD (Table 3, Figure 2 ). The additional use of ATG led to no differences in survival outcomes or incidences of acute or chronic GVHD (hazard ratio [HR], 1.254; P ¼ .651 in acute GVHD and HR, 0.827; P ¼ .540 in chronic GVHD). HLAmismatch/haploidentical HSCT was not associated with a high incidence of acute or chronic GVHD compared with HLA-matched donors (HR, 1.141; P ¼ .760 in HLA-full matched vs. HLAmismatched and HR, 1.236; P ¼ .590 in HLA-full matched vs. haploidentical donors) (see Supplemental Figure 3 in the online version). Toxicities associated with the FMT regimen are described in Table 3 . All non-hematologic toxicities occurred within 50 days after allo-HSCT (median, 8 days after allo-HSCT), and most of the adverse events were tolerable and manageable with a < 30% incidence.
Lymphoma Recurrence and Progression
Thirty (33.7%) patients developed recurrence or progression of lymphoma after allo-HSCT. The median time to disease relapse or progression was 7.2 months (range, 0.8-28.9 months) after allo-HSCT, and the cumulative incidence rate at 1 and 3 years was 20.5% and 33.1%, respectively (Figure 1) . Among the 30 patients, 5 developed disease relapse more than 1 year after allo-HSCT. More than one-half (n ¼ 17; 57%) of these relapsed patients had a poor disease status during the pre-HSCT period; these included CR in 7 patients, PR in 6, SD in 7, and PD in 10. At the last follow-up, 27 patients had died owing to lymphoma progression, and only 3 patients were alive. However, all remained in refractory disease status Figure 4 in the online version) and in patients initially diagnosed with BM-involved lymphoma (43.8% vs. 19.8% for BM involvement vs. absence of BM involvement; P ¼ .012) (see Supplemental Figure 4 in the online version).
Prognostic Factors Influencing Survival Outcomes After the FMT Regimen
To identify the factors affecting survival outcomes in those who received the FMT regimen, each of the clinical and transplantationrelated factors were assessed. In univariate analyses, fewer lines of chemotherapy before allo-HSCT (relative risk [RR], 1.39; P ¼ .041), chemosensitive disease (RR, 2.03; P ¼ .018), late relapse after first-line chemotherapy (RR, 1.98; P ¼ .022), having a graft from a young donor (RR, 1.99; P ¼ .022), an overall grade 0 to II acute GVHD (RR, 8.41; P < .001) (Figure 3) , and mild chronic GVHD (RR, 0.46; P ¼ .006) (Figure 4) were significantly associated with better OS (see Supplemental Table 1 in the online version). In addition, favorable DFS was associated with the following clinical factors: less exposure to chemotherapy prior to allo-HSCT (RR, 1.89; P ¼ .032), chemosensitive disease (RR, 1.81; P ¼ .041), and late relapse after first-line chemotherapy (RR, 1.80; P ¼ .043). Disease status at transplantation (RR, 2.70; P ¼ .018) and BM involvement of lymphoma at initial diagnosis (RR, 2.03; P ¼ .043) affected relapse, whereas no prognostic factor was a significant predictor of NRM (see Supplemental Table 1 in the online version).
According to multivariate analyses (Table 4) , chemorefractory status at transplant (HR, 2.45; 95% CI, 1.276-4.895; P ¼ .010), early relapse after first-line chemotherapy (HR, 2.101; 95% CI, 1.010-4.321; P ¼ .009), grade III to IV acute GVHD (HR, 11.212; 95% CI, 4.112-29.655; P < .001), and no mild chronic GVHD (HR, 0.448; 95% CI, 0.113-0.698; P ¼ .016) were significant independent predictors of poor OS, whereas chemorefractory status at transplantation (HR, 2.336; 95% CI, 1.541-4.198; P ¼ .023), early relapse after first-line chemotherapy (RR, 1.706; 95% CI, 0.784-3.548; P ¼ .023), the presentation of grade III to IV acute GVHD (HR, 7.985; 95% CI, 2.561-15.549; P < .001), and no mild chronic GVHD (HR, 0.501; 95% CI, 0.265-1.321; P ¼ .041) were significantly associated with poor DFS. In addition, lymphoma-involved BM status at initial diagnosis (HR, 3.223; 95% CI, 1.301-7.265; P ¼ .008), late relapse after first-line chemotherapy (RR, 2.654; 95% CI, 1.155-4.559; P ¼ .040), and chemorefractory status at pre-transplantation (HR, 2.453; 95% CI, 1.259-4.154; P ¼ .015) were associated with a higher cumulative relapse rate (Table 4 ) (see Supplemental Figure 4 in the online version). No risk factors were associated with a higher cumulative NRM. Other variables (including patient age, gender, time from diagnosis to transplantation, stem cell source, degree of HLA matching, and usage of ATG) were not independent prognostic factors for survival outcomes.
Survival Outcomes and GVHD Incidences After Allo-HSCT With the FMT Conditioning Regimen
We conducted a relationship analysis between the post-transplant GVHD and survival outcomes. Although there were no statistical differences between any grade acute GVHD and no acute GVHD, subgroup analyses according to severity of acute GVHD, patients with overall grade 0 to II acute GVHD showed more favorable DFS than overall grade III to IV (RR, 5.40; P < .001) (see Supplemental Table 1 in the online version) (Figure 3) . Then, in the case of chronic GVHD, the existence of some chronic GVHD showed more positive survival outcomes than no chronic GVHD. In subgroup analyses, the improvement of the OS and DFS were observed in the group with mild chronic GVHD; there was no survival benefit in the group with moderate to severe GVHD, same as the group with no chronic GVHD (RR, 0.50; P ¼ .016) (see Supplemental Table 1 in the online version) (Figure 4 ).
Discussion
We recently reported favorable clinical outcomes (acceptable NRM and cumulative incidence of relapse) of allo-HSCT using the Survival Outcomes of Allo-HSCT With FMT Regimen for Aggressive NHL this study, we investigated a more substantial number of patients for an extended follow-up duration at a single center to compare the feasibility of an FMT regimen as a homogenous RIC protocol for allo-HSCT. The approach had excellent feasibility and a very low early NRM rate (2.8% in all cohorts). In addition, our cohort underwent allo-HSCT under adverse conditions relative to previous reports: although our subjects were older (median, 49 years vs. median, 40-45 years at transplantation, although younger patients were analyzed in this study compared with the general age of onset in patients with NHL), 22, 23 had advanced disease (44.9% with chemorefractory disease before transplantation), suffered approximately 80% earlier relapse after first-line chemotherapy, had heavily pretreatment chemotherapy (a median of 4 lines of conventional chemotherapy), and experienced many auto-HSCT failures (approximately 37%). Survival outcomes at 3 years were 47.1% for OS, 45.4% for DFS, and about 10% for NRM, which are encouraging results compared with previous reports. 24, 25 Also, previous studies had mainly focused on allo-HSCT for the indolent subtype of NHL, 5,26,27 but most (93%) patients included in this study were diagnosed with aggressive NHL at the initial diagnosis. And, in the survival analysis, there was no difference of OS and DFS between the indolent group and the aggressive group of our cohort. Therefore, it is indirectly suggested that aggressive NHL could be enough to perform allo-HSCT using this FMT conditioning regimen. In addition, BM engraftment occurred in 100% of patients within a reasonable time, and all transplant-associated adverse events were acceptable and tolerable. About 58% of patients with chemorefractory disease reached CR status after transplantation, and among them, 30% of patients maintained CR status for more than 5 years after allo-HSCT even in this very unfavorable subgroup.
Because the RIC regimen has been reported to be a little more suitable for refractory or relapsed NHL, RIC regimens have been used in various ways in different transplant centers. 28 Also, retrospective data have revealed that these regimens show reasonable OS and DFS with acceptable NRM and low relapse rates. 10, 29, 30 Although the optimal regimen remains to be determined, reported contrasting results. 35, 36 Thus, the impact of low-dose TBI on transplant outcomes remains controversial in patients undergoing allo-HSCT for hematologic malignancies. However, malignant lymphoma cells are generally considered to be sensitive to radiation therapy; thus, TBI may be an important tool in the setting of allo-HSCT for NHL using the RIC regimen. 14 Moreover, Freytes et al published supporting results that TBIcontaining conditioning substantially improves PFS especially in patients with NHL after auto-HSCT failure. 37 Another problem with the TBI-based RIC regimen is that it may be significantly associated with an increase in acute GVHD grade III to IV. However, acute GVHD results in our study showed very favorable data; with only 10% grade III to IV acute GVHD compared with 30% in another study. 38 Based on a combination of previously reported data and our results, we suggest that FluMel alkylating agents followed by 4 fractionated doses of 800 cGy in a TBI regimen is a reasonable strategy with acceptable transplant-related toxicity. Kekre et al compared the FluBu and FluMel-based regimens in 136 patients undergoing RIC HSCT for lymphoma, and reported that the FluBu regimen resulted in improved survival outcomes with low risks for acute GVHD and NRM. 25 Our FluMel-based regimen also showed very favorable NRM (approximately 10%) and a much lower rate of acute GVHD (34% for any grade of acute GVHD and 10% in grade III-IV acute GVHD) than previous data. It is encouraging that the incidence of non-hematologic complications, such as oral mucositis (21%) and febrile neutropenia (50%), which are closely associated with TBI and melphalan, was not high in our cohort. Baron et al 39 compared the outcomes of 394 patients with acute myeloid leukemia who received FluBu or FluMel. The FluMel was associated with a lower relapse incidence (HR, 0.5; P ¼ .01) and a trend toward a higher NRM with similar OS and DFS. In conclusion, our FMT regimen is an effective transplant strategy, and it shares some of the benefits of FluMel-based and TBI-based regimens. The other primary objective of this study was to identify risk factors associated with transplant outcomes after applying our regimen. Similar to previous studies, 5, 25, 26, 40 we found that factors such as chemorefractoriness and early relapse after first-line chemotherapy (< 12 months) were independently associated with poor transplant outcomes (OS, DFS, and relapse rate). Patients with mild chronic GVHD had better OS and DFS than those with no chronic GVHD or moderate to severe chronic GVHD, and patients with acute GVHD grade III to IV had the poor OS and DFS. Also, Urbano et al 3 reported that the association between GVHD and relapse rate differs among histologic subtypes of NHL. Considering the tolerable chronic GVHD (mild) and the low incidence of acute GVHD in our cohort, we suggest an essential role of the GVL effect in reducing relapse rates. This might translate into an OS outcome advantage in patients with NHL. According to subgroup analyses of the very high-risk group with chemorefractory disease at transplantation, the FMT regimen was associated with a relatively good OS of 30% at 3 years (see Supplemental Figure 5 in the online version); in a previous series of 144 patients with NHL receiving FluMel-based allo-HSCT, the 3-year rate of OS was only 17% in patients with chemorefractory disease. 41 It is generally known that GVHD risk and transplant-related risk are higher for haploidentical transplants than matched transplants in NHL. Because specific information on the efficacy of haploidentical transplantation in NHL remains limited, a direct comparison with other data is not possible. However, in a study of 97 patients undergoing haploidentical HSCT using a post-transplant cyclophosphamide-based regimen, Lacerda et al 42 reported favorable 4-year OS and PFS rates of approximately 42% and 30%, respectively. Similarly, our cohort contained a relatively large number of haploidentical (n ¼ 17; 19.1%) and mismatched (n ¼ 13; 16.6%) transplants, and OS and DFS rates were 31% and 30%, respectively. No significant differences in OS or PFS were observed between well-matched and haploidentical donors at 3 years (see Supplemental Figure 3 in the online version). Thus, our FMT regimen might show favorable transplant outcomes without regard to the degree of HLA matching. Nevertheless, the vast majority of patients who were refractory to systemic chemotherapy at the time of transplantation relapsed after allo-HSCT and then died owing to disease progression. Complete successful donor engraftment and the presence of mild chronic GVHD did not seem to enhance the GVL effect sufficiently to overcome disease resistance in this group. Further studies are necessary to find ways to improve clinical outcomes for these highrisk patients. For example, early adoption of allo-HSCT in patients with rapid relapse (< 12 months) after first-line chemotherapy, or development of a treatment strategy that yields the maximal efficacy in terms of systemic chemosensitivity status during the time of transplant should be evaluated as potential strategies in a future study. Our study has several limitations. It was a retrospective analysis, and the histopathologic subtypes of NHL were heterogeneous, although the majority of patients had an aggressive pathologic subtype. Thus, patient characteristics were diverse, and there were concerns that statistical bias was likely to occur owing to the small cohort size. Second, a relatively small number of patients were included, which prevents firm conclusions.
Conclusion
In conclusion, we confirmed that reduced-intensity allo-HSCT with our FMT regimen shows favorable transplant outcomes in patients with relapsed or refractory aggressive NHL, including low regimen-related toxicity and excellent donor stem cell engraftment. The FMT regimen might be a useful therapeutic option for some patients with NHL who are chemosensitive before allo-HSCT and who have delayed relapse after first-line chemotherapy accompanied by mild chronic GVHD. However, this therapeutic modality needs to be assessed in prospective trials. We are currently conducting a clinical study to compare the clinical outcomes with MAC regimen.
Clinical Practice Points
Although new therapeutic approaches were developed and adopted to refractory or relapsed NHL, allo-HSCT is still one of the most attractive therapeutic strategies in multi-drug resistant or rapidly refractory aggressive NHL. However, allo-HSCT itself has inherently therapy-related complications; it is difficult to shift to all-HSCT easily. Therefore, we have sought a method to maximize the transplant efficacy while minimizing transplant-related complications. To achieve this purpose, reduced-intensity conditioning was found to have the best results. Among several RIC regimens, moreover, the FMT regimen showed reasonable survival outcomes with tolerable adverse events in this retrospective analysis, especially for the patients with NHL who are chemosensitive before allo-HSCT and who have delayed relapse after first-line. 
